phosphorylcholine has been researched along with Cancer of Head in 9 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Perifosine is an oral alkylphospholipid that inhibits AKT phosphorylation and has shown preclinical antitumor activity in head and neck cancer cell lines and xenografts." | 2.72 | A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. ( Ansari, R; Argiris, A; Cohen, E; Dancey, J; Esparaz, B; Karrison, T; Lu, Y; Mauer, A; Pins, M; Vokes, E; Wong, S, 2006) |
| " In addition, at the highest dosage group in rats, an increase in white blood cell counts (WBC) was observed." | 2.67 | Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. ( Drogendijk, TE; Oosterom, R; Planting, AS; Pronk, LC; Stoter, G; Verweij, J, 1994) |
| "Perifosine was not metabolized and displayed slow elimination, with a terminal half-life of 137 (+/- 20) hours and an apparent volume of distribution of 11." | 1.33 | Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. ( Schellens, JH; van Blitterswijk, WJ; Verheij, M; Vink, SR, 2005) |
| "In vivo, the response of human KB squamous cell carcinoma xenografts was measured after treatment with perifosine, irradiation, and the combination." | 1.33 | Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. ( Begg, AC; Lagerwerf, S; Mesman, E; Schellens, JH; van Blitterswijk, WJ; Verheij, M; Vink, SR, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, L | 1 |
| Lin, YD | 1 |
| Elrod, HA | 1 |
| Yue, P | 1 |
| Oh, Y | 1 |
| Li, B | 1 |
| Tao, H | 1 |
| Chen, GZ | 1 |
| Shin, DM | 1 |
| Khuri, FR | 1 |
| Sun, SY | 1 |
| Vink, SR | 2 |
| Schellens, JH | 2 |
| van Blitterswijk, WJ | 2 |
| Verheij, M | 2 |
| Lagerwerf, S | 1 |
| Mesman, E | 1 |
| Begg, AC | 1 |
| Argiris, A | 1 |
| Cohen, E | 1 |
| Karrison, T | 1 |
| Esparaz, B | 1 |
| Mauer, A | 1 |
| Ansari, R | 1 |
| Wong, S | 1 |
| Lu, Y | 1 |
| Pins, M | 1 |
| Dancey, J | 1 |
| Vokes, E | 1 |
| Pronk, LC | 1 |
| Planting, AS | 2 |
| Oosterom, R | 1 |
| Drogendijk, TE | 1 |
| Stoter, G | 3 |
| Verweij, J | 3 |
| Avila, MA | 1 |
| Otero, G | 1 |
| Cansado, J | 1 |
| Dritschilo, A | 1 |
| Velasco, JA | 1 |
| Notario, V | 1 |
| Gandia, D | 1 |
| Armand, JP | 1 |
| Patel, V | 1 |
| Lahusen, T | 1 |
| Sy, T | 1 |
| Sausville, EA | 1 |
| Gutkind, JS | 1 |
| Senderowicz, AM | 1 |
| Planting, A | 1 |
| van der Burg, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Of Perifosine In Patients With Recurrent Or Metastatic Head And Neck Cancer[NCT00062387] | Phase 2 | 46 participants (Actual) | Interventional | 2003-05-31 | Terminated (stopped due to Administratively complete.) | ||
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
4 trials available for phosphorylcholine and Cancer of Head
| Article | Year |
|---|---|
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carc | 2006 |
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, | 1994 |
Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male | 1993 |
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colore | 1992 |
5 other studies available for phosphorylcholine and Cancer of Head
| Article | Year |
|---|---|
c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; | 2010 |
Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Ce | 2005 |
Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; G2 Phase; Head and | 2006 |
Activation of phospholipase D participates in signal transduction pathways responsive to gamma-radiation.
Topics: Carcinoma, Squamous Cell; Choline; Enzyme Activation; Gamma Rays; Glycerophospholipids; Glycerylphos | 1993 |
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2 Protein Kinase; Cell Cycle; Cell Division; Cyc | 2002 |